Qi Wu
Impact in
- Infectious Diseases top 10%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
-
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Ferroptosis and cancer prognosis
Papers in
-
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 12
- Ferroptosis and cancer prognosis 5
- Occupational and environmental lung diseases 3
-
- Inflammasome and immune disorders 5
- Co-authors
- Yao Zhou (14 shared papers)Tongtong Xu (3 shared papers)Weikun Zhao (2 shared papers)Xianmei Zhou (11 shared papers)Chunyi Wang (5 shared papers)Yongran Cheng (5 shared papers)Xingwei Zhang (5 shared papers)Jiake Tang (5 shared papers)
- Journals
- Evidence-based Complementary and Alternative Medicine (8 papers)Oxidative Medicine and Cellular Longevity (4 papers)Journal of Infection (3 papers)Breast Cancer Research and Treatment (3 papers)Frontiers in Pharmacology (3 papers)
- Partner nations
- ChinaJapanUnited States
In The Last Decade
Qi Wu
93 papers receiving 1.6k citations
Qi Wu's Hit Papers
Peers
Comparison fields: 5 of 124
- Infectious Diseases 190
- Pulmonary and Respiratory Medicine 305
- Pharmacology 81
- Cancer Research 130
- Neurology 104
Countries citing papers authored by Qi Wu
This map shows the geographic impact of Qi Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qi Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qi Wu more than expected).
Fields of papers citing papers by Qi Wu
This network shows the impact of papers produced by Qi Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qi Wu. The network helps show where Qi Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Qi Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 97 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis Hit paper breakdown → | 2022 | 277 |
| 2 | 2021 | 157 | |
| 3 | 2021 | 60 | |
| 4 | 2020 | 57 | |
| 5 | 2021 | 53 | |
| 6 | 2023 | 42 | |
| 7 | 2010 | 41 | |
| 8 | 2020 | 37 | |
| 9 | 2011 | 36 | |
| 10 | 2019 | 34 | |
| 11 | 2022 | 33 | |
| 12 | 2020 | 32 | |
| 13 | 2019 | 32 | |
| 14 | 2018 | 31 | |
| 15 | 2017 | 30 | |
| 16 | 2018 | 25 | |
| 17 | 2022 | 24 | |
| 18 | 2011 | 23 | |
| 19 | 2017 | 23 | |
| 20 | 2009 | 22 |
About Qi Wu
Qi Wu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Cancer Research and Surgery, having authored 97 papers that have together received 1.6k indexed citations. Recurring topics across this work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Inflammasome and immune disorders (5 papers), Ferroptosis and cancer prognosis (5 papers), Advanced Polymer Synthesis and Characterization (3 papers), Medical and Biological Ozone Research (3 papers), Intensive Care Unit Cognitive Disorders (3 papers), Cancer-related molecular mechanisms research (3 papers) and Occupational and environmental lung diseases (3 papers). The work is most often cited by research in Infectious Diseases (190 citations), Pulmonary and Respiratory Medicine (305 citations), Pharmacology (81 citations), Cancer Research (130 citations) and Neurology (104 citations). Qi Wu has collaborated with scholars based in China, Japan and United States. Frequent co-authors include Yao Zhou, Tongtong Xu, Weikun Zhao, Xianmei Zhou, Chunyi Wang, Yongran Cheng, Xingwei Zhang, Jiake Tang, Mengyun Zhou and Zhanhui Feng. Their work appears in journals such as Evidence-based Complementary and Alternative Medicine, Oxidative Medicine and Cellular Longevity, Journal of Infection, Breast Cancer Research and Treatment and Frontiers in Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.